Weekly update|Companies|Recruiting|Promote|Post a job

Vigil Neuroscience

Founded: 2020

Location: Cambridge, MA

Employee range: 11 - 50

Clinical stage: Clin2

Therapy area: ALSP

Drug types: NEU, RAR, GEN

Lead product: VGL101

Product link: https://www.vigilneuro.com/pipeline

Funding: $98M IPO Jan 2022; $90M B Aug 2021; $50M A Dec 2020

vigilneuro.com

linkedin.com

job board

Short description:

Microglia-based Therapeutics for Neurodegenerative Diseases

Drug notes:

Also Clin0 other leukodystrophies; undisclosed Clin0 Alzheimer's

Long description:

Vigil Neuroscience is specializing in developing transformative medicines for neurological disorders, particularly Alzheimer's disease and other neurodegenerative conditions. Their scientific approach centers on microglia, the immune cells of the brain, to develop innovative therapeutics. Microglia become dysfunctional in neurodegenerative diseases. Thus, Vigil Neuroscience integrates cutting-edge neuroscience research with advanced drug discovery technologies to identify treatments that can selectively target microglia and restore brain homeostasis. Through their commitment to scientific rigor and clinical translation, Vigil Neuroscience aims to advance the understanding and treatment of neurological disorders, potentially offering new hope to patients and caregivers worldwide.

Jobs:

VP, Regulatory Affairs & Quality

Watertown, MA|100+ days ago

Main

Contact: recruit@workinbiotech.com